Tadasuke Shimokawaji

Long-term safety and efficacy of benralizumab in patients with severe, uncontrolled asthma: 1-year results from the BORA phase 3 extension trial

William W. Busse, Eugene R. Bleecker, J Mark FitzGerald et al. · The Lancet Respiratory Medicine · 2018 · 298 citations

Asthma, Rheumatology, Extension Trial +10

IgG4-positive Pulmonary Disease

Hideo Kobayashi, Tadasuke Shimokawaji, Soichiro Kanoh et al. · Journal of Thoracic Imaging · 2007 · 70 citations

Asthma, Inflammatory Lung Disease, Advanced Lung Disease +17

Brigatinib in Japanese Patients With ALK-Positive NSCLC Previously Treated With Alectinib and Other Tyrosine Kinase Inhibitors: Outcomes of the Phase 2 J-ALTA Trial

Makoto Nishio, Tatsuya Yoshida, Toru Kumagai et al. · Journal of Thoracic Oncology · 2020 · 67 citations

<scp>IL</scp>‐33 stimulates <scp>CXCL</scp>8/<scp>IL</scp>‐8 secretion in goblet cells but not normally differentiated airway cells

Tsuyoshi Tanabe, Tadasuke Shimokawaji, Soichiro Kanoh et al. · Clinical & Experimental Allergy · 2014 · 48 citations

A multicenter cohort study of osimertinib compared with afatinib as first-line treatment for EGFR-mutated non-small-cell lung cancer from practical dataset: CJLSG1903

Kentaro Ito, Masahiro Morise, Kazushige Wakuda et al. · ESMO Open · 2021 · 44 citations · Full text